We can’t show the full text here under this license. Use the link below to read it at the source.
Durability of Effectiveness Between Users of Once-Weekly Semaglutide and Dipeptidyl Peptidase 4 Inhibitors (DPP–4i) in US Adults with Type 2 Diabetes
How Long Once-Weekly Semaglutide and DPP-4 Inhibitors Stay Effective in US Adults with Type 2 Diabetes
AI simplified
Abstract
Semaglutide users experienced a 0.56% lower average at two-year follow-up compared to DPP-4i users.
- The reduction in HbA1c from baseline was 0.61% greater for semaglutide compared to DPP-4i.
- After adjustments, the odds of achieving an HbA1c level below 7% were 2.16 times greater for semaglutide users.
- Semaglutide was associated with a 1.03 kg/m² greater reduction in compared to DPP-4i.
- Users of semaglutide had 2.27 times greater odds of reducing their BMI category than those on DPP-4i.
- Semaglutide users were less likely to require additional glucose-lowering treatments or insulin compared to DPP-4i users.
AI simplified
Key numbers
0.56%
Reduction
Two-year follow-up levels in semaglutide users vs DPP-4i users.
1.03 kg/m²
Reduction
Change in from baseline to follow-up for semaglutide users vs DPP-4i users.
2.16×
Higher Odds of Target Achievement
Odds of achieving < 7% for semaglutide users vs DPP-4i users.